Introduction 24
Lung disease accounts for the majority of the morbidity and mortality in cystic fibrosis 25 (CF) (1). Bacteria typically found in airway secretions of CF patients include Staphylococcus 26
aureus, Hemophilus influenzae, Pseudomonas aeruginosa, Burkholderia cepacia complex, 27
Stenotrophomonas maltophilia, and Achromobacter species (2). Many of these bacteria have 28 been associated with a decline in lung function in CF (3-6). However, other microorganisms 29 have been isolated from CF lung fluids in recent years including nontuberculous mycobacteria 30 (NTM), anaerobic bacteria, and fungi. While the isolation of some of these microorganisms is 31 temporally associated with deterioration in baseline health in some individuals, it is not clear 32 whether they are relevant pathogens in all patients. Clinicians must discern how to proceed if 33 one of these organisms is isolated in the absence of clinical manifestations, changes in lung 34 function, or radiographic changes. In addition, the clinician must also balance the potential for 35
Furthermore, patient NTM isolates do not always match environmental NTM isolates, matching 70 in 22% -41% of cases when the same MAC species were isolated (14, 16). Nonetheless, certain 71 environmental precautions may reduce exposure. Simple environmental controls implemented at 72 home that may reduce exposure to NTM include increasing the temperature of hot water heaters 73 to greater than 130 o F, installing large droplet shower heads to reduce aerosolization, avoiding 74 tap water rinses of equipment and avoiding tap water mouth rinses prior to sputum collection, 75 and avoiding peat moss dust exposure by wearing a facemask and moistening the soil prior to 76 working with it (18, 20). It is not clear, however, whether these risk modifications impact the 77 development of NTM lung disease. Recent reports of the transmissibility of M. abscessus 78 species in two outpatient CF clinics is worth noting given the previous experience of lack of 79 human to human transmissibility of NTM lung disease (21, 22). Although both reports describe 80 the transmissibility of M. abscessus ssp. massiliense, it is unclear as to whether the risk of 81 transmission is restricted to only this subspecies or whether it may be generalized to all M. 82 abscessus or even other NTM isolates. Therefore, close collaboration with the infection control 83 team and abiding by infection control procedures in CF and bronchiectasis clinics, including 84 respiratory isolation for patients with M. abscessus is warranted in outpatient as well as inpatient 85 settings to prevent transmission of M. abscessus in high risk situations. 86
The diagnosis of NTM lung disease is based on criteria outlined by the ATS including a 87 combination of clinical, radiographic, and microbiologic elements (9). It is worth noting that in 88 most circumstances and for most NTM respiratory isolates (especially MAC), one positive 89 culture, especially with low numbers of organisms, smear negative, or growth on liquid media 90 only, is not adequate for establishing a diagnosis of NTM lung disease. A presumptive diagnosis 91 based on clinical and radiographic features is equally inappropriate for the initiation of empiric 92 therapy. As such, longitudinal monitoring and multiple cultures may be required before a 93 diagnosis of NTM lung disease is firmly established. Further contributing to this conundrum is 94 the well-recognized waxing and waning of radiographic abnormalities, without overall 95 radiographic progression, that is known to occur in patients with NTM lung disease regardless of 96 treatment status. Establishing a more certain diagnosis prior to committing to treatment of NTM 97 lung disease is thus required. Over-diagnosis results in the unnecessary exposure to complicated 98 drug regimens, and under-diagnosis may result in the development of progressive lung disease 99 with irreversible loss of lung function from inadequate treatment. 100
The decision regarding whether to treat NTM lung disease must therefore balance the 101 risks and benefits of treatment versus observation. Individualized patient factors include the risk 102 of progression, goals of therapy (sputum conversion versus suppression), status of co-morbid 103 medical conditions (gastroesophageal reflux, sinus disease, and bronchiectasis), medication 104 tolerance, and patient acceptance (Fig. 1) . Similarly, the intensity of the NTM regimen should 105 be proportionate to disease severity and goals of therapy. In the case of MAC lung disease, the 106 treatment options range from observation to thrice weekly oral therapy to daily therapy plus 107 parenteral therapy. Special attention regarding macrolide use for anti-inflammatory purposes is 108 warranted to avoid the development of resistance in macrolide susceptible NTM lung disease 109 (23-27). Recent CF guidelines have re-affirmed the need to screen patients at baseline and then 110 every six to twelve months (28 practice pattern, even without clear supporting data in the literature, is to begin with an intensive 150 treatment regimen including both parenteral and oral agents followed by de-escalation to an 151 inhaled and oral regimen after a period of weeks or months. The timing and specifics of this 152 transition can be particularly variable given the essential need to avoid monotherapy and to 153 maintain a multidrug regimen with effective non-parenteral agents; the efficacy of which must be 154 weighed against the risks of toxicity and the technical challenges of extended use of parenteral 155 agents. Consultation with a pulmonary disease, infectious disease, and/or NTM expert is 156 generally recommended. Common treatment regimens for NTM lung disease are given in the 157 including commonly prescribed off-label doses and uses. Sources include the pharmacy formulary of The Hospital for Sick Children in Toronto, ON, which is based upon product inserts and the published literature. The doses given are general guidelines, and may vary somewhat between institutions. It is recommended that the clinician consult his/her institution's pharmacy, product inserts, and published literature before prescribing these drugs. Consultation with a pulmonary disease, infectious disease and/or NTM expert to individualize treatment regimens is recommended. †Consider alternative antibiotic if erm gene (encoding for inducible macrolide resistance) detected or inducible macrolide resistance noted. ** Serum concentrations should be monitored and aim for a maximum serum concentration (Cmax) in the range of 80-120 mg/L with a minimum serum concentration (Cmin) of <1 mg/L. Alternatively, peak levels may also be used with a target peak serum level between 20 and 40 35 ug/mL. It is known that CF patients generally have an increased volume of distribution and more rapid clearance which may require higher dosing than others without CF. 
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